KBC Group NV Has $102.15 Million Stock Position in Stryker Corporation $SYK

KBC Group NV lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 10.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 310,863 shares of the medical technology company’s stock after selling 34,837 shares during the quarter. KBC Group NV’s holdings in Stryker were worth $102,147,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Godfrey Financial Associates Inc. bought a new stake in Stryker during the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new position in shares of Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter worth about $28,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Stryker Stock Down 0.0%

Shares of Stryker stock opened at $319.78 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a market capitalization of $122.59 billion, a PE ratio of 37.01, a price-to-earnings-growth ratio of 2.05 and a beta of 0.77. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a 50-day simple moving average of $312.69 and a two-hundred day simple moving average of $336.71.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Canaccord Genuity Group decreased their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. reduced their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Barclays cut their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.